Two independent Swedish studies demonstrated that patients with DMab-associated T1D had a higher risk of anti-CCP positive RA [42] and of anti-thyroid peroxidase and anti-thyroglobulin positive thyroiditis [43]. This evidence concerns the gene TPO and thyroid gland disorder.